ProCE Banner Activity

Testing Before Treating: Molecular Determinants of Optimal Therapy for NSCLC

Slideset Download
Download these slides from a live webinar to learn more about the current guidelines and expert recommendations for evidence-based biomarker testing to guide treatment decision-making in the management of patients with NSCLC.

Released: July 29, 2022

Expiration: July 28, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Craig Mackinnon

Craig Mackinnon, MD, PhD

Professor
Direct Division of Genomic Diagnostics and BioInformatics
University of Alabama at Birmingham
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Genentech TEXT Only

Janssen administered by Scientific Affairs

Lilly

Novartis Pharmaceuticals Corporation

Partners

AMP

ProCE Banner

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Genzyme/Sanofi, iTeos, Surface; researcher (paid to institution): Amgen, Celgene, Johnson and Johnson, Merck, Novartis, Trizell.

Craig Mackinnon, MD, PhD

Professor
Direct Division of Genomic Diagnostics and BioInformatics
University of Alabama at Birmingham
Birmingham, Alabama

Craig Mackinnon, MD, PhD: has no relevant financial relationships to disclose.